Pharmaceutical Industry in China - An In Depth Analysis of Multinational and
Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market
Drivers, Restraints, Opportunities & Challenges” provides you with a
detailed investigation of the market size, segmentation, key players, SWOT
analysis, influential Government policies, and business and economic
environments. The report is supported by over 196 tables & figures within
142 pages. The Chinese biopharmaceutical market is presented as follows:
To Read The Complete Report with TOC :-
·
By
Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN,
SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK,
NOVARTIS)
·
By
Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
·
Company
financials, sales & revenue figures historical to Q2 2013
·
China
GDP, economic growth, export (bulk drug, formulations) figures
·
Indian
health expenditure as a function of GDP
·
Growth
change figures of emerging and developing countries (India, Russia, China,
Brazil)
·
Economic
growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain,
Japan, Canada)
·
Projected
figures of strategic emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics include:
·
Key
strengths, weaknesses and threats influencing leading player position within
the market
·
Top
Five Contract Pharmaceutical Export Markets of China
·
Major
players within China’s leading therapeutic markets (e.g., cancer, allergy,
liver disease)
·
Multinational
penetration into the Chinese Pharma Market
·
Comprehensive
product portfolios, R&D activity and pipeline therapeutics
·
M&A
activity and future strategies of top Chinese pharmacos
·
Economic
indicators, trade policy, merchandise and commercial trade statistics
·
Gross
Domestic Product of China, historic and projection analysis
·
Chinese
economic outlook in comparison to advanced economies
·
Three
Tier ‘Pharmerging’ Markets with Potential for Significant Growth
·
Prescription
drug sales distribution channels in China
·
Major
biogeneric products in China
Forecast projections and future growth rates are provided to
give you a forthcoming perspective of this growing industry. Current
developments relating to patent expirations, government funding, and
regulations are discussed. The emerging trends that appear in key
sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines
are elucidated and analysed.
What you will gain:
·
An
in-depth understanding of the Chinese biopharmaceutical market and it’s
environment
·
Current
market facts, figures and product lines of key players in the industry
·
An
insight into how generic therapeutics will propagate the Chinese
biopharmaceutical market
·
Knowledge
of how the Chinese biopharma market will integrate into the global healthcare
market
·
Information
on key regulatory and government policies
·
Data
on levels of private and publically funded biopharma studies in China
·
Strategies
on how to adapt and restructure current business models to this industry
To Buy a Copy Of This Report:-
This report tackles key concerns to the Chinese
biopharmaceutical market such as:
·
Lack
of regulatory policy and legislation
·
Reimbursement
schemes and payers concerns
·
Funding
and government sponsorship issues
·
International
scepticism of Chinese safety and efficacy therapeutic profiles
This report will tell you if the companies mentioned are:
·
Strong,
competitive players
·
Pooling
their resources for specific growth and therapeutic areas
·
Investing
strategically in R&D
·
Have
a history of strategic M&A activity
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
No comments:
Post a Comment